The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease

Clinical and Experimental Rheumatology

Volumn 25, Issue 4 SUPPL. 45, 2007, Pages

  Mumcu, Gonca ^a,b   Inanc, Nevsun ^a   Yavuz, Sule ^a   Direskeneli, Haner ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Beh et's disease; Etiopathogenesis; Immune responses; Infection

Indexed keywords

ALPHA INTERFERON; AZITHROMYCIN; BENZATHINE PENICILLIN; CD28 ANTIGEN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHOLERA TOXIN B SUBUNIT; COLCHICINE; ERYTHROMYCIN; FAMCICLOVIR; GAMMA INTERFERON; GEMCITABINE; HEAT SHOCK PROTEIN; HLA B51 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOTEICHOIC ACID; MACROLIDE; MINOCYCLINE; PEPTIDE; PEPTIDE 336 351; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALPHA DEFENSIN; CYTOKINE; HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADAPTIVE IMMUNITY; ARTHRITIS; ARTICLE; BEHCET DISEASE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DENTAL CARIES; ERYTHEMA NODOSUM; FOLLICULITIS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; INCIDENCE; INNATE IMMUNITY; MONOTHERAPY; MOUTH INFECTION; MOUTH ULCER; NONHUMAN; PERIODONTAL DISEASE; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS; ANTIGEN EXPRESSION; CHLAMYDIA PNEUMONIAE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; HEREDITY; HISTOPATHOLOGY; IMMUNOREGULATION; MICROORGANISM; MOUTH FLORA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TH1 CELL;

BEHCET SYNDROME; FEMALE; HERPES LABIALIS; HUMANS; MALE; ORAL ULCER; SEX FACTORS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 35448933685     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. SAKANE T, TAKENO M, SUZUKI N, INABA G: Behçet's disease. N Engl J Med 1999; 341: 1284-91.
2. EVREKLIOGLU C: Current concepts in the etiology and treatment of Behçet's Disease. Surv Ophthalmol 2005; 50: 297-350.
3. AL-OTAIBI LM, PORTER S, POATE TW: Behçet's disease: A review. J Dent Res 2005; 84: 209-22.
4. CAKIR N, DERVIS E, BENIAN O et al.: Prevalance of Behçet's disease in rural western-Turkey: A preliminary report. Clin Exp Rheumatol 2004: 22(Suppl. 34): S53-S58.
5. DIRESKENELI H: Behçet's Disease: Infectious etiology, new auto-antigens and HLA-B51. Ann Rheum Dis 2001; 60: 996-1002.
6. GÜL A: Behçet's disease: An update on the pathogenesis. Clin Exp Rheumatol 2001;19 (Suppl.24): S6-S12.
7. YAZICI H, YURDAKUL S, HAMURYUDAN V: Behçet's Syndrome. Curr Opin Rheumatol 1999;11:53-57.
8. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behçet syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
9. WAKABAYASHI T, MORIMURA Y, MIYAMATO Y, OKADA AA: Changing patterns of ofintraocular inflammatory disease in Japan. Ocul Immunol Inflamm 2003; 11: 277-86.
10. YOSHIDA A, KAWASHIMA H, MOTOYAMA Y et al.: Comparison of patients with Behçet's disease in 1980s and 1990s. Ophthalmology 2004; 111:4: 810-15.
11. TUGAL-TUTKUN I, ONAL S, ALTAN-YAYCIOGLU R, ALTUNBAS HH, URGANCIOGLU M: Uveitis in Behçet's Disease: An analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-80.
12. SEYAHI E, UGURLU S, SEYAHI N et al.: A survey of socioeconomic status in Behçet's Syndrome. XI International Conference on Behçet's disease. Clin Exp Rheumatol 2004; (Supp 34): S88, A27 (abstract).
13. ISOGAI E, OHNO S, KOTAKE S et al.: Chemiluminescence of neutrophils from patients-with Behçet's Disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 1990; 35: 43-48.
14. YOSHIKAWA K, KOTAKE S, SASAMOTO Y, OHNO S, MATSUDA H: Close association of Streptococcus sanguis and Behçet's Disease. Nippon Ganka Gakkai Zasshi 1991; 95: 1261-7.
15. MIZUSHIMA Y: Behçet's Disease Research Committe of Japan, Skin hypersensitivity of streptococal antigens and the induction of systemic symptoms by the antigens in Behçet Disease, J Rheumatol 1989; 16: 506-11.
16. MIZUSHIMA Y, MATSUDA T, HOSHI K, OHNO S: Induction of Behçet's Disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15: 1029-30.
17. KANEKO F, TOJO M, SATO M, ISOGAI E: The role of infectious agents in the pathogenesis of Behçet's disease. Adv Exp Med and Biol 2003; 528: 181-3
18. KANEKO F, OYAMA N, NISHIBU A: Streptococcal infection in the pathogenesis of Behçet's Disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997; 38; 444-54.
19. ISOGAI E, ISOGAI H, KOTAKE S, OHNO S, KIMURA K, OGUMA K: Role of Streptococcus sanguis and traumatic factors in Behçet's disease. J Appl Res 2003; 3: 64-75.
20. TOJO M, YANAGIHORI H, ZHENG X et al.: Bes-1 DNA fragment encoding streptococcal antigen in skin lesions from patients with Behçet's disease. J Appl Res 2003; 3: 232-8.
21. MIURA T, ISHIHARA K, KATO T et al.: Detection of heat shock proteins but notsuperantigen by isolated oral bacteria from patients with Behçet's disease. Oral Microbiol Immunol 2005; 20: 167-71.
22. ZOUBOULIS CC, KOTTER I, DJAWARI D et al.: Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. Yonsei Med J 1997; 38: 411-22.
23. GÜL A, INANC M, OCAL L, ARAL O, KONICE M: Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 2000; 59: 622-5.
24. FIETTA P: Behçet's disease: Familial clustering and immunogenetics. Clin Exp Rheumatol 2005; 23(Suppl. 38): S96-S105.
25. DIRESKENELI H: Autoimmunity vs autoinflammation in Behçet's disease: do weover-simplify a complex disorder? Rheumatology 2006; 45:1461-5.
26. + cytotoxic Tlymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis Rheum 2004; 50: 3658-62.
27. KURHAN-YAVUZ S, DIRESKENELI H, BOZKURT N et al.: Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol. 2000; 120: 162-6.
28. SARUHAN-DIRESKENELI G, UYAR FA, CEFLE A et al.: Expression of KIR and C-typelectin receptors in Behçet's disease. Rheumatology (Oxford) 2004; 43: 423-7.
29. TAKENO M, KARIYONE A, YAMASHITA N et al.: Excessive function of peripheral blood-neutrophils rom patients with Behçet's disease and from HLA-B51 transgenic mice. Ann Rheum 1995; 38: 426-33.
30. NISHIYAMA M, TAKAHASHI M, MANAKA K, SUZUKI S, SAITO M, NAKAE K: Microsatellite polymorphisms of the MICA gene among Japanese patients with Behçet's disease. Can J Ophthalmol 2006; 41: 210-5.
31. MUNOZ-SAA I, CAMBRA A, PALLARES L et al.: Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Behçet's disease. Scand J Immunol 2006; 64: 77-82.
32. AHMAD T, WALLACE GR, JAMES T et al.: Mapping the HLA association in Behçet's disease: A role for tumor necrosis factor polymorphisims? Ann Rheum 2003; 48: 807-13.
33. AKMAN A, SALLAKCI N, KACAROGLU H, YAVUZER U, ALPSOY E, YEGIN O: Relationship between periodontal findings and TNF-α gene 1031 T/C polymorphisim in Turkish patients with Behçet's disease. Clin Exp Rheumatol 2006; 24 (Suppl. 42): S5 (Abstract).
34. DUYMAZ-TOZKIR J, GÜL A, UYAR FA, OZBEK U, SARUHAN-DIRESKENELI G: Tumour necrosis factor-alpha gene promoter region-308 and -376→A polymorphisims in Behçet's disease. Clin Exp Rheumatol 2003; 21(Suppl. 30): S15-8.
35. LEE YJ, KANG SW, PARK JJ et al.: Interleukin-18 promoter polymorphisims in patients with Behçet's disease. Hum Immunol 2006; 67: 812-8.
36. KARASNEH J, HAJEER AH, BARRETT J, OLLIER WE, THORNHILL M, GÜL A: Association of spesific interleukin 1 gene cluster polymorphisim with increased suspectibility for Behçet's disease. Rheumatology (Oxford) 2003; 42: 860-4.
37. YANAGIHORI H, OYAMA N, NAKAMURA K, MIZUKI N, OGUMA K, KANEKO F: Role of IL-12B promoter polymorphisim in Adamantiades-Behçet's Disease susceptibility: An involvement of Th1 immunoreactivity against streptococcus sanguis antigen. J Invest Dermatol 2006; 126: 1534-40.
38. ZOUBOULIS CC: HLA-independent antibacterial host response toward Th1 immunity mediated by IL-12: A new concept for the pathogenesis of Adamantiades- Behçet's disease. J Invest Dermatol 2006; 126: 1444-7.
39. AMOURA Z, DODE C, HUE S et al.: Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet disease. Arthritis Rheum 2005; 52: 608-11.
40. ATAGUNDUZ P, ERGUN T, DIRESKENELI H: MEFV mutations are increased in Behçet's disease and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21: S35-7.
41. CALGUNERI M, ERTENLI I, KIRAZ S, ERMAN M, ÇELIK I: Effect of prophylacticbenzathine penicilline on mucocutaneous sysmptoms of Behçet's Disease. Dermatology 1996; 192: 125-8.
42. MUMCU G, ERGUN T, ELBIR Y et al.: Clinical and immunological effects of azithromycinin Behçet's disease. J Oral Pathol Med 2005; 34: 13-6.
43. CALGUNERI M, KIRAZ S, ERTENLI I, BENEKLI M, KARAARSLAN Y, CELIK I: The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial. Arthritis Rheum 1996; 39: 2062-5.
44. MEALEY B, KLOKKEVOLD P: Periodontal medicine. Clinical periodontology W.B. Saunders 9th edition, United States of America 2002; 229-52.
45. STEWART JE, MUMCU G, WALLACE G, STANFORD MR, FORTUNE F: Effects of serum and saliva from patients with Behçet's disease on epithelial and inflammatory cell responses. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-94.
46. ISOGAI E, ISOGAI H, KOTAKE S: Antibody cross reactivity from sera of patients with-Behçet's disease with synthetic peptides that have homologies with proteins from Streptococcus sanguis. J Appl Res 2002; 2: 185-91.
47. HIROHATA S, OKA H, MIZUSHIMA Y: Streptococcal-related antigens stimulate production of IL-6 and interferon-γ by T cells from patients with Behcet's disease. Cellular Immunology 1992; 140: 410-9.
48. MOCHIZUKI M, SUZUKI N, TAKENO M et al.: Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Imunol 1994; 24: 1536-43.
49. MUMCU G, ATALAY T, ERGUN T, ARITAN N, EKSIOGLU-DEMIRALP E, DIRESKENELI H: Cytokine response to in vitro Streptococcus sanguis in Behçet's disease. 10th International Conference on Behçet's disease, 27-29 June, Berlin, Germany.
50. CELENLIGIL-NAZLIEL H, KANSU E, EBERSOLE J: Periodontal findings and systemic antibody responses to oral microorganisms in Behçet's Disease. J Periodontol 1999; 70: 1449-56.
51. CARL W, HAVENS J, KIELICH CDT: Behçet's Disease: Dental and oral soft tissue complications. Quint Int 2000; 31: 113-6.
52. NAKAE K, AGATA T, MAEDA K, MASUDA K, HASHIMOTO T, INABA G: Behçet's Disease, pathogenic mechanism and clinical future: Case control studies on Behçet's Disease. University of Tokyo Press, 1981, 41-9.
53. MUMCU G, ERGUN T, INANC N et al.: Oral health is impaired in Behçet's disease and associate with disease severity. Rheumatology 2004; 43: 1028-33.
54. MUMCU G, INANC N, ELBIR Y, ERGUN T, YAVUZ S, DIRESKENELI H: Low serum mannose binding lectin levels predispose to S.mutans colonization in Behçet's disease. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-93.
55. YIANG Y, MAGLI L, RUSSO M: Bacterium-dependent induction of cytokines in mononuclear cells and their pathologic consequences in vivo. Infect Immunol 1999; 67: 2125-30.
56. HATEMI G, BAHAR H, UYSAL C et al.: The pustular skin lesions in Behçet's syndrome are not steril. Ann Rheum Dis 2004; 63: 1450-2.
57. MERTENS D, KOETTER I, GUENAYDIN I, FRESKO I, YAZICI H, MUELLER C: Expression of α defensins HNP-1 in Behçet's disease: Effector molecules of spontaneous and pathergy induced papulopustular lesions? Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-93.
58. LEHNER T: The role of Heat shock proteins in Behçet's disease. Immunology of Behçet disease 2003, Swets & Zeitlinger Publishers, The Netherlands, 113-20.
59. DIRESKENELI H, EKSIOGLU-DEMIRALP E, YAVUZ S et al.: T cell responses to 60/65 kDa heat schock protein derived peptides in Turkish patients with Behçet's disease. J Rheumatol 2000; 27: 708-13.
60. DIRESKENELI H, SARUHAN-DIRESKENELI G: The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 2003; 21(Suppl. 30): S44-8.
61. LEHNER T, LAVERY E, SMITH R, VAN DER ZEE R, MIZUSHIMA Y, SHINNICK T: Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome. Infect Immun 1991; 59: 1434-41.
62. KIBAROGLU A, EKSIOGLU-DEMIRALP E, AKOGLU T, DIRESKENELI H: T and NK cells subset changes with microbial extracts and human HSP60-derived peptides in Behçet disease. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S59-63.
63. HIROHATA S, HASHIMOTO T: Abnormal T cell responses to bacterial superantigens in Behçet's disease (BD). Clin Exp Immunol 1998; 112: 317-24.
64. HENNEKE P, MORATH S, UEMATSU S et al.: Role of Lipoteichoic acid in the phagocyte response to group B Streptococcus. J Immunol 2005; 174: 6449-55.
65. CUCHACOVICH M, MERINO G, YAMAMOTO JH et al.: Behçet's disease patients present high levels of deglycosylated anti-lipoteichoic acid IgG and high IL-8 production after lipoteichoic acid stimulation. Clin Exp Rheumatol 2005; 23(Suppl. 38): S27-S34.
66. ELBIR Y, TULUNAY A, OZILHAN G et al.: Toll like receptors in etiopathogenesis of Behçet's disease Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-93.
67. DURRANI O, WALLACE GR, HAMBURGER J et al.: Toll like receptors (TLRs) expression in oral ulcer biopsies from Behçet's disease (BD) patients: A role for the innate immune syste in BD. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-93.
68. KULABER A, TENTUR SP, TUGAL-TUTKUN I, GUL A, KANEKO F, SARUHAN DIRESKENELI G: The cellular response to αB-crystalin and streptococcal BES-1 peptides in Behçet's disease. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-95.
69. TOJO M, ZHENG X, YANAGIHORI H et al.: Detection of herpes virus genomes in skin lesions from patients with Behçet's disease and other related inflammatory diseases. Acta Derm Venereol 2003; 83: 124-7.
70. SOHN S, LEE ES, BANG D, LEE S: Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998; 8: 21-3.
71. SOHN S, BANG D, LEE ES, KWON HJ, LEE SI, LEE S: Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice. Br J Dermatol 2001; 145: 799-804.
72. SOHN S, LUTZ M, KWON HJ, KONWALINKA G, LEE S, SCHIRMER M: Therapeutic effects of gemcitabine on cutaneous manifestations in an Adamantiades- Behçet's disease-like mouse model. Exp Dermatol 2004; 13: 630-4.
73. FRESKO I, UGURLU S, OZBAKIR F et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome. Clin Exp Rheumatol 2005; 23 (Suppl. 38): S67-S70
74. KRAUSE I, MONSELISE Y, MILO G, WEINBERGER A: Anti Saccharomyces cerevisiae antibodies - a novel serologic marker for Behçet's disease. Clin Exp Rheumatol 2002 (Suppl. 26): S21-4.
75. AYASLIOGLU E, DUZGUN N, ERKEK E, INAL A: Evidence of chronic Chlamydiapneumoniae infection in patients with Behçet's Disease. Scand J Infect Dis 2004; 36:428-30
76. LABRO M-T: Immunolgical effects of macrolids. Curr Opin Infect Dis 1998; 11: 681-8
77. KAYA TI, TURSEN U, BAZ K, IKIZOGLU G, DUSMEZ D: Severe erythema nodosum due to Behçet's disease responsive to erythromycin. J Dermatolog Treat 2003; 14: 124-7.
78. YURDAKUL S, MAT C, TUZUN Y et al.: A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001; 44: 2686-92.
79. STANFORD M, WHITTALL T, BERGMEIER LA et al.: Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behçet's disease. Clin Exp Immunol 2004; 137: 201-8.
80. MATZINGER P: The danger model: a renewed sense of self. Science 2002; 296: 301-5.
81. MEDZHITOV R, JANEWAY CA JR: Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.